View printer-friendly version

Download PDF

Emergent BioSolutions Recognized by Security Magazine Among Best Security Organizations

Company’s Protective Services Chief Also Recognized Among Top Security Practitioners

LANSING, Mich.–(BUSINESS WIRE)–Jan. 8, 2009–Emergent BioSolutions (NYSE:EBS) was named recently to Security magazine’s “Security 500: The Biggest and Best Security Organizations.”

The publication cites U.S.-based companies in 16 sectors. Emergent BioSolutions was measured in the industrial and manufacturing sector. It is the first year Emergent has been recognized.

“It’s a tremendous honor and extremely important to our business to be recognized in this way,” Fuad El-Hibri, Emergent CEO, said. “Our customers place a premium on our ability to demonstrate secure conditions for manufacturing our products.”

Jeff Hauk, Chief of Protective Services for Emergent BioSolutions, was also recently named to the first-ever list of “20 Under 40” by Security Director News. Chosen from more than 100 nominees, Hauk was recognized for his potential to influence the security industry in the future.

In describing those who were recognized, the publication’s editor Rhianna Daniels wrote, “These individuals represent the top 20 security practitioners under 40 years of age. They are the future of this industry.”

Hauk is a graduate of Central Michigan University. He is a graduate of R.L. Oatman and Associates, a highly regarded and respected executive protection academy, where he was designated an Executive Protection Specialist. Hauk has achieved the highly respected professional designation as a Certified Protection Professional (CPP), from ASIS International, as well as Certified Anti-Terrorism Specialist (CAS) by the Anti-Terrorism Accreditation Board, and Professional Emergency Manager (PEM) by the State of Michigan Emergency Management and Homeland Security Division. He is certified in Crime Prevention through Environmental Design (CPTED) and as a PPCT (Pressure Point and Control Tactics) Defensive Tactics and Ground Avoidance/Ground Escape instructor.

Hauk has gained further education and certification in various security specialties from: University of Louisville (National Crime Prevention Institute), Michigan State University (Criminal Justice Department), Louisiana State University (Academy of Counter Terrorism), New Mexico Tech (EMRTC), Department of Homeland Security and the Emergency Management Institute.

“As security becomes a more integral part of a business, security professionals are being asked to know more about their company’s business objectives than they ever have before,” according to Daniels. “These individuals were chosen with this in mind.”

Hauk began his career with Emergent as a security officer, and has held his current position since 2004.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immune-related biologic products, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, typhoid, tuberculosis, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax procurement; our ability to obtain new BioThrax sales contracts with the U.S. government; our plans to pursue label expansions and improvements for BioThrax; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s quarterly report on Form 10-Q for the quarter ended September 30, 2008 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.